In addition, we also found that HSA-Trx administration ameliorated the further increase in liver injury markers and exacerbation of liver fibrosis associated with the progression of NASH (Fig. 2). The gene discussed is TXN; the disease is metabolic dysfunction-associated steatohepatitis.